Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Agios Pharmaceuticals (AGIO) over the last 10 years, with Q3 2025 value amounting to $58.1 million.

  • Agios Pharmaceuticals' Shares Outstanding (Diluted Average) fell 50.23% to $58.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year decrease of 50.23%. This contributed to the annual value of $57.9 million for FY2024, which is 402.1% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $58.1 million, which was down 50.23% from $57.9 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $69.5 million during Q1 2021, with a 5-year trough of $54.6 million in Q1 2022.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $56.8 million (2024), whereas its average is $58.0 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first plummeted by 2155.2% in 2022, then soared by 471.14% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $60.4 million in 2021, then decreased by 9.36% to $54.8 million in 2022, then increased by 1.57% to $55.7 million in 2023, then rose by 4.02% to $57.9 million in 2024, then rose by 0.43% to $58.1 million in 2025.
  • Its last three reported values are $58.1 million in Q3 2025, $57.9 million for Q2 2025, and $57.5 million during Q1 2025.